Q BioMed Inc. (QBIO) EPS Estimated At $-0.29 as of July, 18

June 27, 2018 - By Leslie Harms

Q BioMed Inc. (OTCMKTS:QBIO) Corporate Logo

Q BioMed Inc. (OTCMKTS:QBIO)’s earnings release is awaited by WallStreet on July, 18, according to RTT. Analysts predict $-0.29 earnings per share. That’s $0.00 or 0.00 % from 2017’s earnings of $-0.29. Last quarter $-0.17 earnings per share was reported. Analysts predicts 70.59 % negative EPS growth this quarter. QBIO is touching $3.42 during the last trading session, after increased 0.29%.Currently Q BioMed Inc. is after 0.00% change in last June 27, 2017. QBIO has 16,791 shares volume. The stock underperformed the S&P 500 by 12.57%.

Q BioMed Inc., a biomedical acceleration and development company, focuses on licensing, acquiring, and providing resources to life sciences and healthcare companies.The firm is worth $47.79 million. The firm offers Strontium Chloride SR89, a radiopharmaceutical agent for the treatment of pain associated with metastatic bone cancer.Currently it has negative earnings. It is also developing Man-01, a pre-clinical lead candidate for the treatment of primary open angle glaucoma.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: